TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00335504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oligofructose-enriched inulin
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03489317

Intervention type: BEHAVIORAL
Intervention: lifestyle modification
Description: Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
Study: NCT00335504

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01021527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C
Description: single dose administration of exenatide 10ug by subcutaneous injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: graded glucose infusion
Description: A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: graded glucose infusion
Description: A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: graded glucose infusion
Description: A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: graded glucose infusion
Description: A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: graded glucose infusion
Description: A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
Study: NCT01533935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching tiotropium + olodaterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol
Description: Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
Study: NCT01021527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: graded glucose infusion
Description: A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
Study: NCT01533935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + Olodaterol
Description: tiotropium 5 mcg + olodaterol 5 mcg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: tiotropium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol
Description: Olodaterol 5 mcg once daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study: NCT04887844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection
Description: Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
Study: NCT01533935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study: NCT04887844

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Physical therapy
Description: The study participants underwent a physiotherapy program that included a one-time 15-minute cold therapy using ice packs and closed-kinetic chain quadriceps strengthening program as follows; isometric quadriceps exercise, isokinetic concentric, and eccentric quadriceps exercises with heel slides and squads. These exercises were repeated ten times a day, seven days per week, for eight weeks in total
Study: NCT00261833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha1-proteinase inhibitor
Description: 60 mg/kg body weight/week intravenous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized preparation: 60 mg/kg body weight/week intravenous
Study: NCT00633685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
Study: NCT01533935

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study: NCT00103194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03440437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS118
Description: Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dosing on Days 1, 8 and 15 of each 28 day cycle in combination with FS118 given on days 1, 8, 15 and 22 of each 28 day cycle.
Study: NCT02916030

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vit D
Description: It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vit D
Description: It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
Study: NCT00633685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be empty gelatin capsules that are identical in size and shape to active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
Study: NCT00906763

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chocolate
Description: A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chocolate
Description: A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
Study: NCT01524406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP593
Description: Oral, twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, twice a day.
Study: NCT04707508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg and metformin
Description: Valsartan 80 mg once daily in addition to metformin monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin monotherapy
Study: NCT01259596

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nondirective supportive therapy
Description: weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
Study: NCT00242320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast
Description: to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04526431

Intervention type: DRUG
Intervention: Dosage Forms Oral
Description: Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)

Intervention type: DRUG
Intervention: Dosage Forms Oral
Description: Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)
Study: NCT03489317

Intervention type: BEHAVIORAL
Intervention: lifestyle modification
Description: Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.

Intervention type: DRUG
Intervention: Simvastatin 10mg
Description: Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.

Intervention type: DRUG
Intervention: Simvastatin 10mg
Description: Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.

Intervention type: DRUG
Intervention: Amlodipine 5mg
Description: Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.

Intervention type: DRUG
Intervention: Amlodipine 5mg
Description: Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
Study: NCT04524832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks
Study: NCT00202969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 plus CDDP
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU plus CDDP
Description: 5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
Study: NCT03920371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gamma camera imaging
Description: Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out
Study: NCT02276820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viralym-A
Description: Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment.
Study: NCT01604447

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia prevention with plastic bag
Description: Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hypothermia prevention without plastic bag
Description: Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
Study: NCT00804206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravitreal bevacizumab before panretinal photocoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravitreal Bevacizumab after panretinal photocoagulation
Study: NCT01933919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate
Description: Film-coated tablet containing 25 mg of fluvoxamine maleate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvoxamine maleate
Description: Film-coated tablet containing 25 mg of fluvoxamine maleate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching to fluvoxamine maleate
Study: NCT03788135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cooling
Description: the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cooling
Description: the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cooling
Description: the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cooling
Description: the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
Study: NCT02591563

Intervention type: OTHER
Intervention: procedures
Description: Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
Study: NCT03747653

Intervention type: DRUG
Intervention: ADVATE
Description: Patients will be administered a single dose of ADVATE.

Intervention type: DRUG
Intervention: ADVATE
Description: Patients will be administered a single dose of ADVATE.

Intervention type: DRUG
Intervention: FRSW107
Description: Patients will be administered a single dose of FRSW107 for Injection.

Intervention type: DRUG
Intervention: FRSW107
Description: Patients will be administered a single dose of FRSW107 for Injection.
Study: NCT02361723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-290
Study: NCT04374305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Oral daily per predetermined dosage per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Oral daily per predetermined dosage per protocol.
Study: NCT03894527

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Bout of Exercise
Description: An exercise condition, which will be walking at a moderate intensity (\~70% VO2peak). Time will vary based upon individual fitness levels to burn \~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Bout of Exercise
Description: An exercise condition, which will be walking at a moderate intensity (\~70% VO2peak). Time will vary based upon individual fitness levels to burn \~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
Study: NCT02361723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-290
Study: NCT03894527

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
Study: NCT04656912

Intervention type: PROCEDURE
Intervention: Hyperbaric oxygen therapy
Description: Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
Study: NCT01005108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
Study: NCT03220009

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV
Study: NCT01005108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
Study: NCT01188382

Intervention type: PROCEDURE
Intervention: CSF dynamic investigation
Study: NCT03587558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
Study: NCT03220009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03587558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide
Description: Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
Study: NCT00704743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylindrical cast
Description: Arm cast/immobilization technique for wrist fracture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified sugar tong cast
Description: Arm cast/immobilization technique for wrist fracture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volar dorsal splint
Description: Arm cast/immobilization technique for wrist fracture